Valeant Pharmaceuticals Intl Inc (VRX) : Marble Arch Investments Lp has sold out all of its stake in Valeant Pharmaceuticals Intl Inc during the most recent quarter, according to the disclosure filed by the company on Aug 15, 2016 with the SEC. The investment management company has sold out 930,100 shares of Valeant Pharmaceuticals Intl Inc which is valued at $23,178,092.
Other Hedge Funds, Including , Boothbay Fund Management sold out all of its stake in VRX during the most recent quarter. The investment firm sold 7,632 shares of VRX which is valued $190,189. Columbus Hill Capital Management sold out all of its stake in VRX during the most recent quarter. The investment firm sold 278,000 shares of VRX which is valued $6,927,760.Wfg Advisors Lp boosted its stake in VRX in the latest quarter, The investment management firm added 2,228 additional shares and now holds a total of 2,877 shares of Valeant Pharmaceuticals Intl Inc which is valued at $71,695. Valeant Pharmaceuticals Intl Inc makes up approx 0.02% of Wfg Advisors Lp’s portfolio. Airain Ltd sold out all of its stake in VRX during the most recent quarter. The investment firm sold 10,553 shares of VRX which is valued $231,744.Nebula Capital Management Lp reduced its stake in VRX by selling 88,230 shares or 73.53% in the most recent quarter. The Hedge Fund company now holds 31,770 shares of VRX which is valued at $710,377. Valeant Pharmaceuticals Intl Inc makes up approx 5.48% of Nebula Capital Management Lp’s portfolio.
Valeant Pharmaceuticals Intl Inc opened for trading at $30.17 and hit $30.7695 on the upside on Wednesday, eventually ending the session at $30.27, with a gain of 2.71% or 0.8 points. The heightened volatility saw the trading volume jump to 14,236,056 shares. Company has a market cap of $10,520 M.
On the company’s financial health, Valeant Pharmaceuticals Intl Inc reported $1.40 EPS for the quarter, missing the analyst consensus estimate by $ -0.08 based on the information available during the earnings call on Aug 9, 2016. Analyst had a consensus of $1.48. The company had revenue of $2420.20 million for the quarter, compared to analysts expectations of $2451.77 million. The company’s revenue was down -11.4 % compared to the same quarter last year.During the same quarter in the previous year, the company posted $2.14 EPS.
Many Wall Street Analysts have commented on Valeant Pharmaceuticals Intl Inc. Company shares were Upgraded by Morgan Stanley on Aug 17, 2016 to ” Overweight”, Firm has raised the Price Target to $ 42 from a previous price target of $33 .Company shares were Upgraded by Mizuho on Aug 15, 2016 to ” Neutral”, Firm has raised the Price Target to $ 25 from a previous price target of $11 .Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Underweight”, Firm has raised the Price Target to $ 22 from a previous price target of $19 .
Valeant Pharmaceuticals International Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing manufacturing and marketing a range of branded generic and branded generic pharmaceuticals over-the-counter (OTC) products and medical devices (contact lenses intraocular lenses ophthalmic surgical equipment and aesthetics devices) which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Company’s developed markets segment consists of sales in the United States of pharmaceutical products OTC products and medical device products. The Company’s Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals OTC products and medical device products.